Advanced Solid Tumors, Lymphoma
Conditions
Keywords
Solid Tumors, Lymphoma, G-Quadruplex
Brief summary
This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three weeks of a four week cycle in patients with advanced solid tumors.
Detailed description
Quarfloxin is a first-in-class small-molecule targeted cancer therapeutic derived from the validated fluoroquinolone class of drugs. Quarfloxin was rationally designed to target a G-quadruplex (QPLX) DNA structure and disrupt protein-DNA interactions essential to cancer cells. The QPLX targeted by quarfloxin forms within ribosomal DNA (rDNA) and the QPLX is bound by the nucleolin protein.
Interventions
DRUGQuarfloxin
Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
Sponsors
Cylene Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histologically confirmed solid tumors or lymphomas. * Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy. * One or more tumors measurable on radiograph or CT scan, or evaluable disease (e.g., malignant ascites). * Karnofsky performance status of greater than or equal to 70. * Life expectancy of at least 3 months. * Age at least 18 years. * Patients must have central IV access, or agree to the insertion of a central IV line. * Normal oxygen saturation by pulse oximetry on room air * A negative pregnancy test (if female). * Acceptable liver function as evaluated by laboratory results * Acceptable renal function as evaluated by laboratory results * Acceptable hematologic status as evaluated by laboratory results * No clinically significant urinalysis abnormalities * Acceptable coagulation status as evaluated by laboratory results * Fertile men and women must use effective contraceptive methods during the study.
Exclusion criteria
* Seizure disorders requiring anticonvulsant therapy. * Known brain metastases (unless previously treated and well controlled for a period of greater than or equal to 3 months). * Severe chronic obstructive pulmonary disease with hypoxemia, or an uncorrectable pulmonary compromise. * Major surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug. * Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy. * Pregnant or nursing women. * Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry (6 weeks for nitrosoureas or Mitomycin C). * Unwillingness or inability to comply with procedures required in this protocol. * Known infection with HIV, hepatitis B, or hepatitis C. * Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis. * Patients who are currently receiving any other investigational agent. * Patients who have exhibited allergic reactions to a similar structural compound (e.g., fluoroquinolones, biological agent or formulation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum tolerated dose (MTD) and Dose limiting toxicity (DLT) | Cycle 1 |
| Recommended Phase 2 dose | Cycle 1 |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics (PK) in humans of intravenously administered quarfloxin | One month |
| Evaluation of antitumor activity of quarfloxin by objective radiologic assessment | Every 2 months |
| Pharmacodynamic evaluation of antitumor activity | Monthly |
Countries
United States
Outcome results
None listed